share_log

Short Interest in Aziyo Biologics, Inc. (NASDAQ:AZYO) Drops By 55.6%

Short Interest in Aziyo Biologics, Inc. (NASDAQ:AZYO) Drops By 55.6%

Aziyo Biologics, Inc.（纳斯达克股票代码：AZYO）的空头利率下降了55.6％
kopsource ·  2022/12/15 10:12

Aziyo Biologics, Inc. (NASDAQ:AZYO – Get Rating) saw a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 3,200 shares, a decline of 55.6% from the November 15th total of 7,200 shares. Based on an average daily volume of 21,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.1% of the shares of the company are sold short.

阿齐约生物股份有限公司(纳斯达克：AZYO-GET评级)在11月份看到空头股数的销售额大幅下降。截至11月30日，空头股数共有3200股，较11月15日的7200股下降了55.6%。以日均成交量21,000股计算，目前天数与回补比率为0.2天。目前，该公司0.1%的股份被卖空。

Aziyo Biologics Price Performance

Aziyo生物制品价格表现

NASDAQ:AZYO opened at $3.64 on Thursday. The firm has a market cap of $50.14 million, a PE ratio of -1.28 and a beta of -0.54. Aziyo Biologics has a 12 month low of $3.51 and a 12 month high of $9.01. The company has a quick ratio of 0.83, a current ratio of 1.09 and a debt-to-equity ratio of 1.34. The company's 50-day moving average price is $6.83 and its two-hundred day moving average price is $6.71.

纳斯达克：AZYO周四开盘报3.64美元。该公司市值为5,014万美元，市盈率为-1.28，贝塔系数为-0.54。Aziyo Biologics的12个月低点为3.51美元，12个月高位为9.01美元。该公司的速动比率为0.83，流动比率为1.09，债务权益比率为1.34。该公司的50日移动均线价格为6.83美元，200日移动均线价格为6.71美元。

Get
到达
Aziyo Biologics
Aziyo生物制品
alerts:
警报：

Aziyo Biologics (NASDAQ:AZYO – Get Rating) last released its quarterly earnings results on Monday, November 14th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.07). The firm had revenue of $12.39 million during the quarter, compared to analyst estimates of $12.20 million. Aziyo Biologics had a negative net margin of 77.08% and a negative return on equity of 1,819.23%. On average, equities analysts anticipate that Aziyo Biologics will post -2.63 EPS for the current fiscal year.

阿齐约生物(纳斯达克：AZYO-GET Rating)最近一次发布季度收益报告是在11月14日(星期一)。该公司公布了该季度每股收益(0.73美元)，低于分析师普遍预期的(0.66美元)和(0.07美元)。该公司本季度营收为1239万美元，而分析师预期为1220万美元。Aziyo Biologics的净利润率为负77.08%，净资产回报率为负1819.23%。股票分析师平均预计，Aziyo Biologics本财年的每股收益将达到2.63欧元。

Insider Transactions at Aziyo Biologics

Aziyo Biologics的内幕交易

In related news, Director Highcape Capital, L.P. acquired 735,000 shares of the company's stock in a transaction dated Monday, December 5th. The shares were bought at an average price of $4.75 per share, for a total transaction of $3,491,250.00. Following the acquisition, the director now owns 5,597,604 shares in the company, valued at approximately $26,588,619. The transaction was disclosed in a legal filing with the SEC, which is available through
相关新闻，董事在12月5日星期一的交易中收购了735,000股该公司股票。这些股票是以每股4.75美元的平均价格购买的，总交易额为3,491,250.00美元。收购完成后，董事现在拥有该公司5597,604股，价值约26,588,619美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过
this hyperlink
此超链接
. In related news, Director Highcape Capital, L.P. acquired 735,000 shares of the company's stock in a transaction dated Monday, December 5th. The shares were bought at an average price of $4.75 per share, for a total transaction of $3,491,250.00. Following the acquisition, the director now owns 5,597,604 shares in the company, valued at approximately $26,588,619. The transaction was disclosed in a legal filing with the SEC, which is available through
。相关新闻，董事在12月5日星期一的交易中收购了735,000股该公司股票。这些股票是以每股4.75美元的平均价格购买的，总交易额为3,491,250.00美元。收购完成后，董事现在拥有该公司5597,604股，价值约26,588,619美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过
this hyperlink
此超链接
. Also, CFO Matthew Ferguson bought 22,000 shares of the firm's stock in a transaction dated Monday, December 5th. The shares were acquired at an average price of $4.65 per share, for a total transaction of $102,300.00. Following the completion of the transaction, the chief financial officer now owns 45,217 shares in the company, valued at approximately $210,259.05. The disclosure for this purchase can be found
。此外，首席财务官马修·弗格森在12月5日星期一的交易中购买了22,000股该公司的股票。这些股票是以每股4.65美元的平均价格收购的，总交易额为102,300.00美元。交易完成后，首席财务官现在拥有该公司45,217股，价值约210,259.05美元。关于这次购买的披露可以找到
here
这里
. In the last 90 days, insiders have purchased 765,000 shares of company stock worth $3,625,030. 39.90% of the stock is currently owned by company insiders.
。在过去的90天里，内部人士购买了76.5万股公司股票，价值3,625,030美元。公司内部人士目前持有该公司39.90%的股份。

Hedge Funds Weigh In On Aziyo Biologics

对冲基金买入Aziyo Biologics

A hedge fund recently raised its stake in Aziyo Biologics stock. Endurant Capital Management LP lifted its stake in shares of Aziyo Biologics, Inc. (NASDAQ:AZYO – Get Rating) by 3.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,109,479 shares of the company's stock after purchasing an additional 33,839 shares during the period. Aziyo Biologics makes up about 1.7% of Endurant Capital Management LP's investment portfolio, making the stock its 16th biggest position. Endurant Capital Management LP owned approximately 8.18% of Aziyo Biologics worth $6,601,000 as of its most recent filing with the Securities and Exchange Commission. 24.52% of the stock is currently owned by hedge funds and other institutional investors.

一家对冲基金最近增持了Aziyo Biologics股票。耐久资本管理有限公司(Endurant Capital Management LP)最近向美国证券交易委员会(Securities And Exchange Commission)披露的信息显示，该公司第一季度增持了Aziyo Biologics，Inc.(纳斯达克代码：AZYO-GET Rating)的股份3.1%。该机构投资者持有该公司1,109,479股股票，在此期间又购买了33,839股。Aziyo Biologics在Enurant Capital Management LP的投资组合中约占1.7%，使该股成为其第16大头寸。截至最近向美国证券交易委员会提交的文件，耐久资本管理有限公司拥有Aziyo Biologics约8.18%的股份，价值6,601,000美元。该公司24.52%的股票目前由对冲基金和其他机构投资者持有。

Analyst Upgrades and Downgrades

分析师升级和下调评级

AZYO has been the topic of several recent research reports. Truist Financial lifted their target price on shares of Aziyo Biologics from $8.00 to $10.00 and gave the company a "buy" rating in a research report on Wednesday, November 16th. Piper Sandler lifted their target price on shares of Aziyo Biologics from $9.00 to $10.50 and gave the company an "overweight" rating in a research report on Tuesday, November 15th.

AZYO是最近几份研究报告的主题。Truist Financial在11月16日(周三)的一份研究报告中将Aziyo Biologics的股票目标价从8.00美元上调至10.00美元，并给予该公司“买入”评级。派珀·桑德勒在11月15日周二的一份研究报告中将Aziyo Biologics的股票目标价从9.00美元上调至10.50美元，并给予该公司“增持”评级。

Aziyo Biologics Company Profile

Aziyo生物制品公司简介

(Get Rating)

(获取评级)

Aziyo Biologics, Inc, a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device.

Aziyo Biologics，Inc.是一家再生医学公司，专注于再生医疗产品的开发，以满足植入式电子设备/心血管、矫形/脊柱修复和软组织重建市场。它提供CanGaroo，它将信封与抗生素结合在一起，旨在降低电子设备手术植入后的感染风险。

Recommended Stories

推荐故事

  • Get a free copy of the StockNews.com research report on Aziyo Biologics (AZYO)
  • Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
  • Is Enterprise Products Partners Fairly Valued?
  • Will WhatsApp Partnership Boost MercadoLibre's Earnings?
  • 3 Mid-Caps That Could Double in 2023
  • Mullen Automotive Shares Jump After Signing New Partner
  • 免费获取StockNews.com关于Aziyo生物制品的研究报告(AZYO)
  • 通货膨胀和能源危机是两列相撞的货运列车--以下是如何做好准备的
  • 企业产品合作伙伴是否得到公平评价？
  • WhatsApp合作伙伴关系是否会提振MercadoLibre的收益？
  • 2023年中型股可能翻一番
  • 马伦汽车签署新合作伙伴后股价上涨

Receive News & Ratings for Aziyo Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aziyo Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

获得Aziyo生物制品日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Aziyo Biologics和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发